6 January 2023 - If approved, the vaccine would provide the broadest serotype coverage of any pneumococcal conjugate vaccine in infants and children, and have the potential to help protect against more of the clinically significant remaining burden of disease.

Pfizer today announced that the US FDA accepted for priority review a supplemental biologics license application for its 20 valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine in infants and children 6 weeks through 17 years of age, and for the prevention of otitis media caused by seven of the 20 Streptococcus pneumoniae serotypes contained in the vaccine.

Read Pfizer press release